Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin.
In a randomized, double-blind, controlled study, 28 patients with early scleroderma received dipyridamole (225 mg/day) and aspirin (975 mg/day) or placebo for 1-2 years. No significant clinical or objective laboratory improvement was noted in either group. Platelet survival time, plasma renin activity, and coagulation tests were not predictive of disease course. Biomechanical and vascular tests of the hands correlated with clinical extent of skin induration and presence of finger ulcers, respectively.
D001241:Aspirin / Q000008:administration & dosage* / Q000627:therapeutic use; D001696:Biomechanical Phenomena; D001777:Blood Coagulation / Q000187:drug effects; D001792:Blood Platelets / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004176:Dipyridamole / Q000008:administration & dosage* / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005385:Fingers / Q000503:physiopathology; D006801:Humans; D009068:Movement; D012595:Scleroderma, Systemic / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D012867:Skin / Q000503:physiopathology
D004176:Dipyridamole; D001241:Aspirin